About Us

Your partner for high-quality clinical immunomonitoring

NEOMED-LABS is a contract research organization (CRO) offering high-quality clinical immunology laboratory services. We serve pharmaceutical corporations, biotechnology companies, and healthcare / non-profit organizations with our extensive expertise in delivering quality readouts for the clinical development of vaccines and immunotherapies. Currently, we support clinical vaccine development programs of multinational pharma companies. Our staff consists of over 60 experienced, dedicated scientists and technical experts, and our projects are supported by an extensive network of key opinion leaders (KOLs) as scientific advisors and consultants. We conduct GCLP-compliant immunomonitoring activities to support Phase I to Phase IV vaccine clinical trials. Located in the Montreal area (Quebec, Canada), an important scientific hub in North America and host to four major universities and several biotechnology companies, we benefit from cutting-edge technology platforms, as well as state-of-the-art laboratories with BSL 2 and BSL 3 facilities.

Our core competencies

  • Immunomonitoring testing with available high-throughput testing (liquid handlers and automated readers), rapid data analysis, biostats, and interim and final reports. Sample analysis available for exploratory studies, mid-scale studies for preclinical and Phase I, and large-scale studies for Phase II to post-marketing studies. Capacity of generating over 150K results annually, ensuring efficient support of large clinical studies, including post-licensure trials.
  • Assay development, qualification, validation, and testing: technical experts in custom assay design, development, method adaptation and technology transfer of immunological assays, including viral and bacterial functional assays, and flow cytometry readouts.
  • Protein optimization services: different bacterial and eukaryotic expression systems are available for protein design and expression optimization, generation and selection of stable cell lines, and characterization of protein biophysical properties (size in solution, folding, stability, affinity, sequence integrity).
  • Project consultancy and management: strong scientific project managers supporting the development and adaptation of immunoassays based on specific needs. Close personal, collaborative, and optimal interactions with our partners. A single and dedicated project manager is assigned to each of our partners’ projects to ensure the best communication, timeline follow-up, and quality.
  • Sample management to support testing laboratories, including logistics, methods of collection, shipping & receiving, preparation, and storage with the highest level of quality. Capacity to store over 500,000 samples. Web-based LIMS system in place to monitor quality, from reception to final testing, to ensure secured data protection, efficiency and quality in sample management, tracking, and associated data.
  • High-quality standards in all our operations, testing procedures, and reporting. Well-established quality management systems (QMS) supported by procedures in accordance with applicable GCP/GLP/GCLP regulations and guidelines. We are compliant with ISO Standard 8655 for critical instruments used in clinical laboratories. We perform regular internal self-audits to ensure continuous improvement of our quality system. We are also regularly audited by independent auditors to ensure compliance, harmonization, and efficiency.

History

1997
1997
2001
2001
2005
2005
2012
2012
2014
2014
2015
2015
2016
2016

1997

IntelliVax​

Montreal-based innovative mucosal vaccine delivery company. Initiated Phase I clinical trial to study the safety and immunogenicity of a nasal proteasome influenza vaccine.

2001

ID Biomedical​

ID Biomedical, a mid-sized vaccine company based in Vancouver, completes the acquisition of Intellivax.

2005

Inauguration of GSK Vaccines North America site, Laval​

Acquisition of ID Biomedical by GSK and inauguration of the GSK Vaccines North America site in Laval. Development of expertise in all areas of the vaccine R&D processes, from discovery to clinical development.

2012

​Launch of NEOMED Institute initiative

Launch of the NEOMED Institute’s initiative with the support of AstraZeneca, Pfizer, and the Government of Quebec. Inauguration of the NEOMED Institute’s small molecules site in their state-of-the-art laboratories in Saint-Laurent (Montreal).

2014

NEOMED Institute Recognized as new CECR

The NEOMED Institute is recognized as a new Centre of Excellence in Commercialization and Research (CECR) with support from the Government of Canada.

2015

Creation of NEOMED-LABS

New pharma partnership with GSK. Creation of a new Centre of Excellence in Biologics and Vaccines and inauguration of NEOMED Institute’s Laval site.

Creation of NEOMED-LABS.

2016

Launch of NEOMED-LABS

Launch of NEOMED-LABS as a contract research organization (CRO) providing high-quality and high-throughput clinical immunomonitoring services. GSK’s entire immunomonitoring team that performed clinical serology testing, including post-licensure activities, is transferred into the new CRO NEOMED-LABS.